Genocea Congratulates Jessica Baker Flechtner, Ph.D. for Recognition on 2016’s 40 Women To Watch Over 40 List

CAMBRIDGE, Mass., Aug. 09, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, is delighted to congratulate Jessica Baker Flechtner, Ph.D., chief scientific officer, who was acknowledged as an honoree on this year’s 40 Women to Watch Over 40 list. The list, founded in 2013, celebrates the achievements of women over 40 who are pushing boundaries in their respective industries.

The 40 Over 40 list highlights an inspiring lineup of women who are reinventing, disrupting and making an impact in their fields. In her role as chief scientific officer, Dr. Flechtner leads a team of scientists and researchers focused on innovation in T cell target discovery and vaccine development for infectious diseases and cancers. Dr. Flechtner has been instrumental in expanding the company’s focus into oncology, establishing important collaborations with leading academic centers to advance the understanding of T cell immune responses to cancers and inform Genocea’s cancer vaccine development strategy.

“This is a well-deserved honor and distinction, and I am delighted to have had the privilege of working closely with Jessica over the past several years. Her many successes are an inspiration to those around her,” said Chip Clark, president and chief executive officer of Genocea. “In addition to being an accomplished scientist, strategist and exemplary leader at Genocea, Jessica serves as a mentor and positive role model for young women interested in pursuing STEM careers, helping to build the next generation of biotech leaders.”

Winners were selected based on a rigorous application and judging process that evaluated three areas: impact, role model and, reinvention and momentum. To view the complete list of 2016 winners, click here: http://fortyover40.com/honorees/.  

About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended), and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.

For media: 	
Liz Bryan 	
Spectrum Science Communications, Inc.
O: 202-955-6222	
[email protected]  

For investors: 
Jonathan Poole
Genocea Biosciences, Inc.
O: 617-876-8191 
[email protected]